Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00898820 · ClinicalTrials.gov registry record
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 80
- Enrollment target
NCT00898820: Completed study, sponsored by Mayo Clinic.
NCT00898820 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00898820 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is looking at blood samples from patients with stage III or stage IV non-small cell lung cancer enrolled in clinical trial MCCRC-RC0524 to determine the effect of pemetrexed disodium on cells.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- GENETIC polymorphism analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00898820
The ClinicalTrials.gov registry entry for NCT00898820 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gene expression analysis is the first listed.
NCT00898820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00898820 about?
NCT00898820 is a clinical study titled "Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524". RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is looking at ...
What is the current status of trial NCT00898820?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2006-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00898820?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00898820?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.